Lab
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings was paid $3.39M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 11% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
MONROE, LA 71203
MONROE, LA 71203
33aNPI1598748782assigned 11/22/2005
33bProvider typeClinical Medical Laboratory
28Total paid$3.39M
24GClaims571,181
24DCodes billed125
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Louisiana
Rank by total paid#16 of 66
Median peer was paid$253K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,816 | $137K | |
| 2019 | 24,640 | $180K | |
| 2020 | 47,679 | $245K | |
| 2021 | 106,042 | $485K | |
| 2022 | 121,632 | $602K | |
| 2023 | 140,100 | $905K | |
| 2024incomplete | 107,272 | $832K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 11% | 2,299 | 2,100 | $385K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 9.0% | 78,841 | 66,474 | $305K |
| 80050 | General health panel | 6.8% | 11,743 | 10,488 | $229K |
| 80053 | Comprehensive metabolic panel | 5.8% | 55,618 | 44,411 | $196K |
| 87507 | 5.5% | 813 | 731 | $186K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.3% | 4,653 | 3,921 | $144K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.2% | 53,482 | 39,347 | $143K |
| 80061 | Lipid panel | 4.1% | 29,296 | 25,500 | $139K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.6% | 9,375 | 8,127 | $121K |
| 87186 | 3.5% | 27,125 | 23,791 | $118K | |
| 87088 | 3.1% | 28,032 | 24,177 | $105K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.0% | 4,551 | 4,146 | $103K |
113 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.0% | 4,552 | $103K |
| 87081 | 3.0% | 21,868 | $101K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.0% | 23,570 | $66K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.9% | 2,998 | $64K |
| 0099U | 1.6% | 429 | $56K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 13,574 | $48K |
| 87070 | 1.4% | 9,843 | $46K | |
| 87077 | 1.3% | 10,954 | $44K | |
| 87486 | 1.3% | 1,854 | $43K | |
| 87581 | 1.3% | 1,854 | $43K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.2% | 2,356 | $42K |
| 81001 | 1.1% | 24,505 | $39K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 527 | $38K |
| 82728 | <1% | 4,782 | $32K | |
| 85027 | <1% | 15,679 | $27K | |
| 82607 | <1% | 4,366 | $26K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,667 | $25K |
| 83020 | <1% | 2,174 | $20K | |
| 84153 | <1% | 2,603 | $20K | |
| 84439 | <1% | 4,974 | $18K | |
| 83735 | <1% | 5,613 | $18K | |
| 82746 | <1% | 2,858 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,827 | $16K |
| 84702 | <1% | 1,629 | $12K | |
| 82784 | <1% | 1,498 | $12K | |
| 85045 | <1% | 4,737 | $12K | |
| 83550 | <1% | 2,901 | $11K | |
| 83615 | <1% | 2,742 | $10K | |
| 83540 | <1% | 3,814 | $10K | |
| 86803 | <1% | 1,402 | $10K | |
| 82378 | <1% | 1,137 | $9K | |
| 84436 | <1% | 3,061 | $9K | |
| 86762 | <1% | 995 | $8K | |
| 0097U | <1% | 58 | $7K | |
| 84479 | <1% | 2,572 | $7K | |
| 82570 | <1% | 3,172 | $7K | |
| 82043 | <1% | 2,763 | $7K | |
| 85610 | <1% | 6,585 | $7K | |
| 84403 | <1% | 439 | $6K | |
| 87427 | <1% | 971 | $6K | |
| 84100 | <1% | 2,327 | $6K | |
| 86140 | <1% | 3,030 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 643 | $6K |
| 86850 | <1% | 1,012 | $5K | |
| 87045 | <1% | 982 | $5K | |
| 87046 | <1% | 978 | $5K | |
| 84550 | <1% | 2,128 | $5K | |
| 85730 | <1% | 2,353 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 203 | $4K |
| 81003 | <1% | 4,993 | $4K | |
| 85652 | <1% | 3,451 | $4K | |
| 82248 | <1% | 1,568 | $3K | |
| 84134 | <1% | 2,631 | $3K | |
| 84481 | <1% | 343 | $3K | |
| 80074 | <1% | 155 | $3K | |
| 86901 | <1% | 1,400 | $2K | |
| 86900 | <1% | 1,402 | $2K | |
| 83880 | <1% | 478 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 47 | $2K |
| 80164 | <1% | 2,506 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 82 | $2K |
| 84165 | <1% | 555 | $2K | |
| 86592 | <1% | 748 | $2K | |
| 80177 | <1% | 1,532 | $2K | |
| 83690 | <1% | 493 | $2K | |
| 80069 | <1% | 897 | $2K | |
| 82565 | <1% | 607 | $1K | |
| 86300 | <1% | 134 | $1K | |
| 83002 | <1% | 90 | $1K | |
| 83001 | <1% | 87 | $1K | |
| 82947 | <1% | 677 | $1K | |
| 84520 | <1% | 520 | $997.83 | |
| 80051 | <1% | 266 | $974.85 | |
| 82150 | <1% | 247 | $825.03 | |
| 87040 | <1% | 154 | $818.75 | |
| 80076 | <1% | 340 | $747.26 | |
| 83525 | <1% | 138 | $703.58 | |
| 82247 | <1% | 311 | $696.37 | |
| 84156 | <1% | 376 | $665.71 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,939 | $664.43 |
| 84155 | <1% | 811 | $647.64 | |
| 82550 | <1% | 312 | $599.67 | |
| 83021 | <1% | 42 | $590.01 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 26 | $575.51 |
| 85018 | <1% | 670 | $468.45 | |
| 81025 | <1% | 96 | $448.06 | |
| 87205 | <1% | 239 | $441.93 | |
| 86038 | <1% | 59 | $401.06 | |
| 84132 | <1% | 820 | $369.47 | |
| 87340 | <1% | 77 | $346.68 | |
| 85014 | <1% | 492 | $302.69 | |
| 86696 | <1% | 17 | $216.08 | |
| 80202 | <1% | 33 | $170.46 | |
| 86431 | <1% | 55 | $148.91 | |
| 86695 | <1% | 17 | $146.25 | |
| 84144 | <1% | 13 | $144.56 | |
| 85007 | <1% | 86 | $117.95 | |
| 84450 | <1% | 93 | $104.42 | |
| 85384 | <1% | 15 | $95.19 | |
| 84703 | <1% | 14 | $74.30 | |
| 85004 | <1% | 16 | $70.98 | |
| 82040 | <1% | 111 | $62.99 | |
| 80156 | <1% | 28 | $46.32 | |
| 84075 | <1% | 55 | $44.78 | |
| 85048 | <1% | 41 | $43.38 | |
| 82465 | <1% | 16 | $39.99 | |
| 84484 | <1% | 15 | $11.10 | |
| 80162 | 0% | 36 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
| S3600 | Stat laboratory request (situations other than s3601) | 0% | 202 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 52 | $0.00 |
| 80185 | 0% | 39 | $0.00 | |
| 80178 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VP)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.